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Key point
HCV is an extremely
diverse RNA virus with 8
known genotypes and 90
known subtypes.
Thematic Miniseries on HCV cureSummary
The hepatitis C virus (HCV) is an extremely diverse virus, subtypes of which are distributed variably
around the world. Viral genotypes may be divided into epidemic subtypes; those that have become
prevalent globally, and endemic subtypes that have a more limited distribution, mainly in Africa and
Asia. The high variability of endemic strains reflects evolutionary origins in the locations where they are
found. This increased genetic diversity raises the possibility of resistance to pan-genotypic direct-acting
antiviral regimens. While many endemic subtypes respond well to direct-acting antiviral therapies,
others, for example genotypes 1l, 3b and 4r, do not respond as well as predicted. Many genotypes that are
rare in high-income countries but common in other parts of the world have not yet been fully assessed in
clinical trials. Further sequencing and clinical studies in sub-Saharan Africa and Asia are indicated to
monitor response to treatment and to facilitate the World Health Organization’s 2030 elimination
strategy.
© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction
The revolution in therapeutic options for the
treatment of the hepatitis C virus (HCV) is one of
the most important medical advances in a gener-
ation and has led the World Health Organisation
(WHO) to propose a plan for elimination by 2030.
Sustained virological response (SVR) rates of more
than 95% have become the norm in high-income
countries (HICs), using treatments that have very
few side effects and are cheap to manufacture,
albeit subject to country-specific pricing differ-
ences.1,2 However, a key weakness of the clinical
research underpinning this plan is that almost all
of it was carried out in HICs, a weakness repeatedly
acknowledged by the international WHO HCV
treatment guidelines committee, that focuses on
the needs of low- and middle-income countries
(LMICs) (Fig. 1).3 Early indications that SVR rates
might not always be as high as expected in some
populations emerged from studies on direct-acting
antiviral (DAA) treatment in Europe and North
America that found diverse genotypes in patients
originating from sub-Saharan Africa.4–6 Subse-
quently, emerging studies investigating response
rates to DAAs in Africa and Asia have confirmed
these initial reports on a larger scale.7
HCV is one of the most genetically diverse hu-
man viruses.8 This genetic diversity, which varies
by geographical region, has not yet been fully
characterised, due to under-sampling in many
parts of the world, meaning that the likelihood of
drug resistance in many viral subtypes has not
been assessed. At the time of writing, 8 genotypesJournal of Hepatology 2021 vol. 75 j 4and 90 subtypes of HCV have been described
with an average pairwise distance of more than
30% between genotypes and an intra-genotype
average pairwise distance of 15% between sub-
types.8 These genotypes may be divided into
genetically conserved epidemic lineages that have
been exported large scale around the world and
more localised highly diverse endemic lineages.
Several endemic lineages have recently been found
to be associated with resistance to some “pan-
genotypic” DAA regimens (in particular those
containing first-generation NS5A inhibitors) and
may represent a threat to the global elimination
plans proposed by the WHO.
Response to treatment in vitro and in clinical
trials in epidemic genotypes prevalent in Europe,
the United States, North Africa, parts of Asia and
the Indian sub-continent (genotypes 1a,1b, 2a, 3a,
4a, 4d and 6a) has been studied in detail. DAAs
with activity against such genotypes have been
termed “pan-genotypic” and have enabled the
WHO to develop a series of guidelines aimed at
elimination of HCV by 2030.3 These guidelines aim
to simplify treatment regimens so that genotyping
(which is expensive and can provide a barrier to
treatment, particularly in LMICs) is not required at
the individual level.
In this review article, we make the case that
there is a need for further population-based
sequencing and real-world clinical studies to
assist policymakers in individual countries to select
more nuanced treatment strategies appropriate to62–473









Fig. 1. Map showing locations of DAA-related studies involving HCV-infected individuals. Details of registered clinical trials
were downloaded from clinicaltrials.org. DAA, direct-acting antiviral.
Key point
10 epidemic lineages (1a,1b,
2a, 2b, 2c, 3a, 4a, 4d, 5a, 6a)
are well described yet there
are many endemic lineages
that are poorly characterised
clinically, but highly preva-
lent, particularly in low
middle-income countries.the local setting, given emerging evidence that
some endemic genotypes present in sub-Saharan
Africa and Asia may respond less well than origi-
nally anticipated to DAAs, particularly first-
generation NS5A inhibitors such as daclatasvir
and ledipasvir.
Methods in brief
A comprehensive review was carried out based on
searching the literature for all endemic genotypes
(excluding the epidemic genotypes 1a,1b, 2a, 3a,
4a, 4d and 6a). The primary source of genetic
sequence data and published references was HCV
GLUE,9 which is a comprehensive dataset of HCV
genetic sequences with associated metadata from
the NCBI. The sequences and metadata are curated
and organised into genotypes and subtypes with
linked relevant PubMed references. The sequences
are linked to a database of polymorphisms known
to be associated with DAA treatment failure or
reduced DAA efficacy in vitro, developed and
maintained by an expert resistance group led by
Public Health England.
A supplemental literature search was conducted
on PubMed to search for every individual endemic
sub-genotype, e.g. “4r” and “treatment” and any
additional studies describing HCV genetic diversity
and related geographic distribution as well as re-
ported treatment outcomes using the following
search terms: “genotype”, “rare”, “unusual” or
“uncharacterised” and “HCV” or “hepatitis C virus”
and “treatment” or “management” or “direct-
acting antiviral” or “DAA” or “interferon-free”.
To show the number and location of completed
and ongoing DAA treatment studies, data were
obtained from www.clinicaltrials.gov. Included
studies were not limited to randomised controlled
trials, provided DAAs were administered to HCV-
infected individuals in the country or countries
where the study was conducted. Studies involving
only healthy volunteers and studies involving useJournal oof the first-generation protease inhibitors telapre-
vir and boceprevir with pegylated-interferon and
ribavirin were excluded. A further 2 studies were
excluded as no information on the country where
the study was conducted could be found.
Data manipulation was carried out in R (version
3.5.3).
Geographical distribution of genotypes
The distribution of HCV genotypes around the
world is highly heterogenous, with the highest
levels of diversity in Asia and sub-Saharan Africa;
paradoxically, these regions are the least sampled
(Fig. 2). The high genetic diversity of HCV in these
locations most likely reflects the evolutionary ori-
gins of HCV subtypes. In contrast, the more heavily
sampled but far less diverse epidemic lineages of
HCV (including 1a, 1b, 2a, 2b, 2c, 3a, 4a, 4d and 6a),
most likely represent a diaspora of exported
founder strains that dispersed rapidly due to
medical and recreational use of injections, blood
transfusions, and operative medical procedures,
peaking during the 20th century. The coincidence
of industrialisation alongside changes in medical
care and an increase in wealth in some countries
has left a legacy of highly sampled relatively
conserved epidemic strains in HICs and a highly
diverse but largely invisible pool of HCV in LMICs.
HCV lineages associated with increased intrinsic
resistance to the NS5A inhibitors, with different
levels of resistance according to the drug and drug
generation, are harboured within this reservoir of
endemic strains and could present a barrier to
global elimination if transmission is not prevented
in affected areas.
Genotype 1a and 1b are the most widespread
genotype 1 lineages, distributed around the globe
by the founder effect (Fig. 3) through the use
of injections in people who inject drugs (PWID)
and within healthcare settings,10 and to a far
lesser extent through sexual11 and verticalf Hepatology 2021 vol. 75 j 462–473 463
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Fig. 2. Global maps illustrating availability of sequence data, distribution of viraemic population and ratio of sequence
data to infected population. (A) HCV genetic sequences greater than 500 nucleotides in length uploaded to GenBank and
curated using HCV GLUE by country (accessed on 4th August 2020). (B) Global distribution of estimated HCV viraemic popu-
lation.50 (C) Ratio of the number of published HCV genetic sequences to the estimated viraemic population per country.
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Thematic Miniseries on HCV curetransmission.12 Genotype 1 is likely to have orig-
inated in West Africa where extremely high levels
of sub-genotypic diversity are evident.13
Genotype 2 is also likely to have originated in
West Africa14 where it is most prevalent and most
diverse (Fig. 4). It dispersed widely within West
African countries most likely as a result of iatro-
genic blood-borne transmission, for exampleJournal of Hepatology 2021 vol. 75 j 4during military medical public health interventions
that aimed to treat the whole population of French
Cameroon between 1921 and 1957 for African
trypanosomiasis, yaws, syphilis and leprosy using
injected treatments. Genotype 2 has also spread to
other parts of the world. It was exported to the
Caribbean by sea as a result of the transatlantic
slave trade; sequences sampled in Martinique62–473
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Gt1 class




















Fig. 3. Genotype 1 genotype and sub-genotype distribution. (A) Global distribution of genotype 1 HCV. (B) Genotype 1
subtype distribution with a focus on the subregions of Africa where genotype 1 is most diverse. Epidemic genotype 1 subtypes
include 1a and 1b. Endemic genotype 1 subtypes include 1c, 1d, 1e, 1f, 1g, 1h, 1j, 1k, 1l and 1m. (C) Genotype 1 subtype diversity
within West Africa (Benin, Ghana, Mali and Nigeria) and Central Africa (Cameroon and Equatorial Guinea). 1* refers to unas-
signed Genotype 1 subtypes.closely resemble those from the Benin–Ghana area
(people in Martinique are known to share ancestry
with populations in present-day Ghana, Togo,
Benin and Nigeria). Genotype 2 also migrated from
South America to Asia, likely at least in part via the
slave trade between Indonesia and Suriname.
Reflecting this history, genotype 2 strains are alsoJournal ofound in the Americas, for example in the USA
(2a,2b), Argentina (2a,2c), Venezuela (2b,2c, 2j, 2s),
Suriname (2e,2f,2j,2o), Brazil (2a,2b,2c) and Hispa-
niola (2r) and in Asia – Indonesia (2e), China (2a),
Japan (2a,2b), Thailand and Vietnam (2a, 2m).15
Genotype 3 is highly prevalent in several re-
gions of the world (Fig. 5), with most heterogeneityf Hepatology 2021 vol. 75 j 462–473 465













Fig. 4. Genotype 2 genotype and sub-genotype distribution. (A) Global distribution of Genotype 2 HCV. (B) Genotype 2
subtype distribution with a focus on the subregions of Africa where it is most diverse. Epidemic Genotype 2 subtypes include
2a, 2b and 2c. Endemic Genotype 2 subtypes include 2d, 2e, 2f, 2i, 2j, 2k, 2l, 2m, 2n, 2o, 2q, 2r, 2s, 2t and 2u.
Key point
Asia and sub-Saharan Arica
host the most diverse HCV
lineages but are the least
well sampled for genomic
data.
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Thematic Miniseries on HCV curein the Indian sub-continent and Southeast Asia.16
The majority of trials have focused on the
epidemic genotype 3a subtype that is prevalent in
the Indian sub-continent and has most successfully
entered populations in HICs. However, genotype
3b17 is also distributed widely in Asia, including
India, China, Malaysia and Thailand. The less well
characterised genotypes 3c (provisional), 3d and 3e
have been found in Nepal, 3f, 3g and 3i in India and
3k in Indonesia.18 Genotype 3 strains are uncom-
monly detected in South and Central America and
in sub-Saharan Africa, but exist in East Africa where
genotype 3h has been found in Somalia and in in-
dividuals originating from this area.19
Genotype 4 HCV (Fig. 6) is likely to have orig-
inated in Central and East Africa where multiple
diverse endemic strains predominate.20 Several
lineages have spread into North Africa and further
afield, of which genotypes 4a and 4d are most
dispersed. Genotype 4a is the most prevalent ge-
notype 4 strain around the world and trans-
mission was amplified in North Africa, particularly
Egypt as a result of unsafe injection practices in
healthcare settings.21 Clinical trials have focused
on this subtype, and to a lesser extent genotype 4d,
a strain introduced to Saudi Arabia during the early
20th century,22 probably from countries in the Horn
of Africa including Ethiopia.23 It has more recentlyJournal of Hepatology 2021 vol. 75 j 4emerged in PWID in Southern Europe and found a
sexually-transmitted niche in men-who-have-sex-
with-men (MSM) in Northern Europe with cross-
over from PWID to MSM likely occurring in urban
centres such as Amsterdam, London, Berlin and
Paris.24 While the globally dispersed genotype 4a
and 4d lineages are well described, others prevalent
in sub-Saharan Africa have only recently been
investigated in clinical studies.
Genotype 5 is the most common genotype in
South Africa25 and has been exported to Europe,
Asia and North America in rare cases (Fig. 7). There
is currently 1 official subtype (5a), however a sec-
ond highly divergent lineage has been identified
in Burkina Faso,26 suggesting that genotype 5 may
be more widespread on the African continent
than previously suspected (official sub-genotypes
require 3 separate sequences from at least 3
infected individuals to be officially confirmed).8
Genotype 6 is the most diverse HCV genotype
and is most prevalent in Southeast Asia (Fig. 8)
where further geographic heterogeneity of sub-
types is evident.27 While the epidemic strain 6a has
been exported widely around the world, other
subtypes are far more spatially structured within
distinct geographical locations. Genotype 6u is
found in Laos28 and Vietnam29 while 6v has been
detected in China and Thailand.30,3162–473
















Fig. 5. Genotype 3 genotype and sub-genotype distribution. (A) Global distribution of Genotype 3 HCV. (B) Genotype 3
subtype distribution with a focus on the subregions of Asia and East Africa where it is most diverse. The epidemic Genotype 3
subtype is 3a. Endemic Genotype 3 subtypes include 3d, 3e, 3f, 3g, 3h, 3i and 3k.Genotypes 7 and 8 have only recently been
identified in individuals originally from the DRC,
Uganda32 and India.33 The distribution of these
subtypes requires further investigation.
Susceptibility to DAAs in non-epidemic
HCV subtypes
Reduced efficacy of DAAs is most often related to
polymorphisms within the NS5A gene in epidemic
subtypes of HCV and this also appears to be the
case with endemic strains.2,3,34 A list of poly-
morphisms predicted to confer resistance is
included in Table S1. This has been well-
documented with the first-generation NS5A in-
hibitors ledipasvir and daclatasvir but may also
affect SVR rates with second-generation inhibitors.
Amino acid polymorphisms associated with resis-
tance within NS3 have been reported in endemic
strains but have not been tested extensively in
clinical trials. Polymorphisms in NS5B are not
common – the well described but uncommon and
unfit S282T polymorphism is associated with
reduced efficacy of sofosbuvir in epidemic lineages.
This has occasionally been detected in subtypes 4r
and 6l but the in vivo impact is unknown.35,36
Resistance-associated substitutions (RASs) in
epidemic genotypes do not often lead to treatmentJournal ofailure in the absence of other risk factors. Cirrhosis
and previous treatment failure are the most com-
mon risk factors associated with treatment resis-
tance; however, it is not yet fully established if such
risk factors are invariably present in DAA failure
with endemic lineages. Further clinical trials are
required to investigate this.
In vitro susceptibility to DAAs
The in vitro efficacy of second-generation NS5A
inhibitors, pibrentasvir and velpatasvir, for infec-
tious clones of genotypes 1a, 1b, 2a, 3a, 4a, 5a, 6a
and 7a is high, in keeping with the pan-genotypic
activity reported in vivo (with the exception of 7a
for which a single case report of SVR following
sofosbuvir and velpatasvir is available).2,3,37 The
presence of RASs is only occasionally associated
with treatment failure in such subtypes, often in
patients with cirrhosis.2
A recent in vitro study investigated the efficacy
of first and later generation NS5A inhibitors
daclatasvir, elbasvir, ledipasvir, pibrentasvir and
velpatasvir against several endemic subtypes (1l,
3b, 3g, 4r, 6u and 6v) using the JFH1 sub-genomic
replicon (SGR-JFH1) backbone and the NS5A gene
of the respective genotype of interest. In this
evaluation, only pibrentasvir had high-level pan-f Hepatology 2021 vol. 75 j 462–473 467






























Fig. 6. Genotype 4 genotype and sub-genotype distribution. (A) Global distribution of Genotype 4 HCV. (B) Genotype 4
subtype distribution with a focus on the regions of Africa where it is most diverse. Epidemic Genotype 4 subtypes include 4a
and 4d. Endemic Genotype 4 subtypes include 4b, 4c, 4e, 4f, 4g, 4h, 4i, 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4s, 4t, 4v and 4w. (C) Genotype
4 subtype diversity within Central (Cameroon, Democratic Republic of Congo and Gabon) and East Africa (Rwanda and Uganda).
4* refers to unassigned Genotype 4 subtypes.
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Thematic Miniseries on HCV curegenotypic activity in vitro.34 NS5A sequences of
genotypes 1l and 4r typically encode a 28M/30R/
31M motif at positions that are associated with a
resistant phenotype in vivo.5 The NS5A Y93H
mutation is also commonly found in genotype 4r-
infected patients in whom treatment has failed.5,6
Subtypes 3b and 3g invariably encode the doubleJournal of Hepatology 2021 vol. 75 j 4NS5A RAS 30K/31M. This double combination has
been shown to confer high-level drug resistance
when introduced into the 3a subtype, suggesting
that subtypes 3b and 3g are more likely to reduce
the effectiveness of NS5A inhibitors.38 The NS5A
sequences of subtypes 6u and 6v encode the 28V/
30S/93S triple polymorphism in 100% (2/2 and 6/6)62–473
Number of sequences 0 1−10 11−100 >100
Fig. 7. Genotype 5 genotype and sub-genotype distribution. Global distribution of Genotype 5 HCV. The shading in Asia
represents a full length and one partial HCV sequence from China51 as well as one full length HCV sequence from India (un-
published), reflecting how rare Genotype 5 HCV is in Asia.
Key point
Clinical trials have involved
treatment of HCV-infected
individuals in high income
countries where epidemic
lineages of HCV are the
most prevalent circulating
virus. Some endemic line-
ages, for example 1l and 4r,
are known to respond less
well to direct-acting anti-
viral treatment than
epidemic lineages.of published 6u and 6v sequences. This triple motif is
associated with substantially reduced effectiveness
of ombitasvir for genotype 6a.39 In the SGR-JFH1
backbone model (containing genotype-specific
NS5A), subtypes 3b and 3g were resistant to dacla-
tasvir, elbasvir, ledipasvir and velpatasvir, while 1l,
4r, 6u and 6v were sensitive to elbasvir and velpa-
tasvir but not to daclatasvir and ledipasvir.34 Clinical
trials are indicated to evaluate the response to
treatment of these subtypes in areas where they
occur commonly.
Clinical trial and real-world experience with
DAAs
Clinical studies have predominantly been con-
ducted in HICs where endemic subtypes occur oc-
casionally, usually in cases of imported infection.
Many large clinical trials in HICs have failed to
identify subtypes within treatment arms making
interpretation challenging. Clinical trials in LMICs
have been carried out in a small number of coun-
tries. These have been observational and have
usually involved only small numbers of patients
without the benefit of sequence analysis for the
detection of resistance.
Some genotype 1 subtypes prevalent in West
Africa have been associated with lower-than-
expected SVR rates to current DAA regimens. Two
studies in the UK have shown that genotype 1l
(prevalent in Nigeria and Cameroon) and several
unclassified genotype 1 subtypes are associated
with lower-than-expected SVR rates.4,5 In 1 UK
study, carried out in an area with a high number of
patients originating from West Africa, only 75% of
African patients infected with genotype 1 subtypes
rarely found in the UK achieved SVR, whereas a
high rate of response was achieved in those infec-
ted with genotypes 1a and 1b.4 Studies in West
Africa are awaited.Journal oEvidence confirming the in vitro resistance profile
of some genotype 3 subtypes has also emerged
recently in clinical studies. In a Chinese single-arm
phase III trial, 89% of patients without cirrhosis
with genotype 3b HCV responded to treatment with
sofosbuvir and velpatasvir while only 50% of those
with cirrhosis achieved SVR.17 Trials of patients
infected with genotype 3g are awaited.
The SHARED study was a single-arm prospec-
tive evaluation of the efficacy and safety of ledi-
pasvir/sofosbuvir in adults diagnosed with
chronic HCV genotype 4 infection in Rwanda.7
Treatment with ledipasvir and sofosbuvir led to
high SVR rates of 93% in patients with the highly
prevalent genotype 4k variant found in Gabon,
the DRC, Uganda and Rwanda; a generic formu-
lation of this treatment has been widely distrib-
uted in sub-Saharan Africa. Patients with
genotypes 4q and 4v also responded well to
treatment, with SVR rates of 90% and 100%,
respectively). In contrast, as predicted in silico,
in vitro and in small numbers of patients in Eu-
ropean trials, genotype 4r was associated with a
far lower-than-expected SVR response to ledi-
pasvir/sofosbuvir of only 56% (27/48 individuals).
The SVR12 response rate among all patients in
the trial with a non-subtype 4r infection was 93%
(234/252 of those treated). Genotype 4r is prev-
alent in several countries in sub-Saharan Africa,
including the DRC, Rwanda, South Africa, Ethiopia
and Malawi and has been detected in Saudi Ara-
bia. Genotype 4r NS5A resistance-associated
polymorphisms (to daclatasvir, velpatasvir and
ledipasvir-based regimens) have also been re-
ported in small numbers of participants in studies
in the UK and France.5,6,40 A phase IV follow-on
study is ongoing in Rwanda (SHARED3) to
investigate the use of sofosbuvir and velpatasvir
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Fig. 8. Genotype 6 genotype and sub-genotype distribution. (A) Global distribution of Genotype 6 HCV. (B) Genotype 6
subtype distribution with a focus on the regions of Asia where they are most diverse. The epidemic Genotype 6 subtype is 6a.
Endemic Genotype 6 subtypes include 6b, 6c, 6d, 6e, 6f, 6g, 6h, 6i, 6j, 6k, 6l, 6m, 6n, 6o, 6p, 6q, 6r, 6s, 6t, 6w, 6xa, 6xb, 6xc, 6xd,
6xe. (C) Genotype 6 subtype diversity within Eastern (China) and South-eastern Asia (Cambodia, Thailand, Vietnam, Myanmar,
Malaysia and Indonesia). 6* refers to unassigned Genotype 6 subtypes.
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Thematic Miniseries on HCV curevoxilaprevir as second-line therapy. Genotypes 4b
(also found in the DRC), 4c and 4g (found in the
DRC and Gabon) and 4l were also detected and
treated in the SHARED study but were present in
very small numbers. Very little or no SVR data are
available for other genotype 4 subtypes not
detected in this study, including 4e (Gabon), 4f
(Cameroon, Algeria), 4h (the DRC), 4m (Egypt), 4n
(Egypt), 4o (Saudi Arabia), 4p (Cameroon), 4sJournal of Hepatology 2021 vol. 75 j 4(Uganda) and 4t (Cameroon).41 Of these, subtype
4b has shown evidence of resistance to ledipasvir
in vitro and merits further study.35
Treatment responses of genotype 6a have also
been well documented both in vitro and in vivo but
other genotype 6 subtypes have not.37,42 Limited
data from clinical trials have highlighted high
SVR12 rates for genotype 6a.2,3 It will be impor-
tant to identify response rates to other genotype 662–473
Key point
We advocate for further
studies to characterise the
prevalence and genetic di-
versity of endemic HCV
lineages in low middle-
income countries to deter-
mine optimal regional
treatment strategies and
facilitate the World Health
Organization’s 2030 elimi-
nation strategy.subtypes where they are prevalent, particularly in
Southeast Asia. Given the presence of a triple RAS
motif in subtypes 6u and 6v and the results of
in vitro assays with first-generation NS5A in-
hibitors daclatasvir and ledipasvir, real-world
studies and clinical trials using these and other
agents (including the generic NS5A inhibitor rav-
idasvir) are eagerly anticipated.
Mis-genotyping by commercial diagnostic assays
As well as affecting treatment outcomes, genetic
variation may also result in difficulties with gen-
otyping HCV subtypes. While an in-depth discus-
sion and summary of the evidence behind the
occurrence of mis-genotyping HCV by commercial
assays is beyond the scope of this review, we
highlight the importance of this issue, particularly
when considering the implications for treatment.
For example, in the SHARED study, several sub-
type 4r samples were mis-typed by an Abbott
assay as genotype 1,7 this assay was also associ-
ated with mistyping of genotype 6 subtypes as
genotype 143 and genotype 7 HCV as genotype 2.44
Implications and future planning
Many genotypes that have not been assessed in large
randomised controlled clinical trials also appear to
respond well to treatment in smaller real-world
studies.2,7,45,46 However, recent in vitro experi-
mental and clinical data have shown that some sub-
genotypes are associated with a reduced suscepti-
bility to current DAA therapies.2,34 Several genotypes
common in parts of sub-Saharan Africa and Asia,
including genotypes 1l, 3b, 3g, 4b, 4r, 6u and 6v
harbour RASs and have evidence of variable levels of
resistance to NS5A inhibitors in vitro. Genotypes 1l,
3b and 4r have also been found to respond less well
than expected to some DAAs in clinical studies. Ge-
notypes 7 and 8 have not yet been assessed in
clinical trials. These genotypes are not rare in
affected countries but are most prevalent in LMICs
where large scale clinical trials have not taken place
due to the absence of highly profitable markets.
Future international regulation and/or political
pressure on the drug industry may be required to
ensure that the WHO HCV elimination target is
achieved and policymakers, patients and treating
physicians should recommend that pharmaceutical
companies based in HICs consider the ethics of ac-
cess to effective treatment for all in addition to
market forces when developing new therapies.
Treating physicians in HICs should consider the
possibility of atypical genotypes in patients who
may have become infected with HCV in sub-
Saharan Africa and Asia – this consideration is
now outlined in the most recent EASL guidelines.2
Those practicing in countries where such geno-
types are common in the population should pref-
erentially use WHO-recommended regimens that
include NS5A inhibitors with a higher barrier toJournal oresistance, such as glecaprevir/pibrentasvir or
sofosbuvir/velpatasvir in preference to first-
generation inhibitors such as daclatasvir or ledi-
pasvir. Sofosbuvir/daclatasvir remains a recom-
mended first-line “pan-genotypic” regimen in the
current WHO treatment guidelines3 – this combi-
nation may be highly effective in some countries
but may not be optimal in others. Retreatment
options for endemic subtypes have only been
partially assessed, typically in very small numbers
of patients. Current guidelines and some small
studies suggest that glecaprevir/pibrentasvir/
sofosbuvir or sofosbuvir/velpatasvir/voxilaprevir
with rare genotypes may be a suitable option for
retreatment in individuals who have undergone
unsuccessful therapy with NS5A inhibitors.2,5,6,47
Development of treatment registries in LMICs
would be of considerable value in tracking real-
world responses to treatment and in quantifying
the risk of onward transmission of resistant
strains. Sub-genotyping has not always been car-
ried out or reported in many clinical trials. While
genotyping is not necessary at the individual
level, population-level genotyping studies
would help individual countries to set up appro-
priate local treatment strategies. Full genome
sequencing can be carried out at relatively low-
cost using technologies such as Illumina and
Oxford nanopore. The highly portable Oxford
nanopore MinION platform (the size of a mobile
phone) has been used to generate full genome
sequences in virus outbreaks all around the
world, including in low-income countries such as
the DRC.48 Such work has not yet been applied to
HCV on a large scale and genetic sequence data is
missing from many LMICs. However, it is feasible
and should be considered.
Of the 71 million people living with HCV in the
world, sub-Saharan Africa,49 South and Central
America and Asia, are home to 10, 3.5 and 31
million people with HCV, respectively, thus sharing
a significant proportion of the burden of HCV
infection.50 Careful consideration needs to be given
to treatment strategies for HCV in these regions –
elimination is within our grasp, but one size does
not necessarily fit all.
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